AMENDMENT TRANSMITTAL LETTER (Large Entity)						Docket No. 50623.26	
Exposication (s): Wouter E. Roorda Serial No. 09/748,412		Filing Date December 21, 2000		Examiner Hieu Phan	G	Group Art Unit 3738	
Invention: Sometime Component For Inhibiting Formation Of Thrombus-Inflammatory Cell Matrix							
TO THE COMMISSIONER FOR PATENTS:							
Transmitted herewith is an amendment in the above-identified application.							
The fee has been calculated and is transmitted as show below.							
CLAIMS AS AMENDED							
	CLAIMS AFTER A		HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE	
TOTAL CLAIMS			20	0	X \$50.00	\$00.00	
INDEP. CLAIMS	INDEP. CLAIMS		8	0	X \$200.00	\$00.00	
Multiple Dependent Claims (check if applicable)						\$00.00	
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT						\$00.00	
 No additional fee is required for amendment. □ Please charge Deposit Account No. 07-1850 in the amount of \$00.00 A duplicate copy of this sheet is enclosed. □ A check in the amount of to cover the filing fee is enclosed. 							
The Commissioner is hereby authorized to charge payment of any necessary fees associated with this communication or credit any overpayment to Deposit Account No. 07-1850							
A duplicate copy of this sheet is enclosed.							
☐ Any additional filing fees required under 37 C.F.R.My6.							
Any patent application processing fees under 87/0/F.R. 1.17/							
Dated: January 4, 2005 Squire, Sanders & Dempsey L.L.P. 1 Maritime Plaza, Suite 300 San Francisco, CA 94111 (415) 954-0200 cc: Docket:							
CC. DOCKEL.				٠.			



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Examiner:

H. Phan

Serial No.:

09/748,412

Wouter E. Roorda

Art Unit:

3738

Filed:

December 21, 2000

Title:

Device And Active Component For Inhibiting

Formation Of Thrombus-Inflammatory Cell Matrix

Commissioner for Patents USPTO P.O. Box 1450 Alexandria, VA 22313-1450

RESPONSE TO OFFICE ACTION

Dear Examiner Phan:

This responds to the Office Action dated October 4, 2004.

Specification amendments begin at page 2.

Claim amendments begin at page 3.

Remarks begin at page 7.